- About Us
- Our Products
- Our Expertise
- Science of Skin
- Mothers & Children
We are a global biopharmaceutical company committed to developing drugs for the treatment of a range of severe skin disorders.
Clinuvel’s lead compound, SCENESSE® (afamelanotide), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe. In February 2012 SCENESSE® was filed for review by the European Medicines Agency for EPP. Further trials of SCENESSE® are underway in the pigmentary disorder vitiligo.
Our website has been developed to help share our expertise on the interaction of light and human skin as well as provide a thorough overview of our global drug development programs.